WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma

Rauscher, Julian Ludwig; Beschorner, Rudi; Gierke, Midea; Bisdas, Sotirios; Braun, Christian; Ebner, Florian; Schittenhelm, Jens

doi:10.1136/jclinpath-2013-202114

Cited by 30 publications

(27 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,23 This differential expression of WT1 in high-grade brain tumors has recently been validated in an in vivo study analyzing human gliomas, which included 442 glioblastomas, 303 astrocytomas, 41 oligodendrogliomas, and 43 oligoastrocytomas. 27 The results showed that WT1 expression in brain tumors increased with WHO grade, older age, and absence of IDH1 mutation. 27 The introduction of a WT1-based vaccine in clinical trials was first described by Oka et al in 2004.…”

Section: Gbm and Wilms Tumormentioning

confidence: 93%

“…27 The results showed that WT1 expression in brain tumors increased with WHO grade, older age, and absence of IDH1 mutation. 27 The introduction of a WT1-based vaccine in clinical trials was first described by Oka et al in 2004. 13,25 The authors reported the effects of the vaccine on breast cancer, lung cancer, and leukemia in 26 patients, reporting tumor regression and no toxicity as a result of the drug.…”

Section: Gbm and Wilms Tumormentioning

confidence: 93%

See 1 more Smart Citation

Wilms tumor 1 gene, CD97, and the emerging biogenetic profile of glioblastoma

Somasundaram

Ardanowski

Opalak

et al. 2014

FOC

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common type of primary brain tumor, and current treatment regimens are only marginally effective. One of the most vexing and malignant aspects of GBM is its pervasive infiltration into surrounding brain tissue. This review describes the role of the Wilms tumor 1 gene (WT1) and its relationship to GBM. WT1 has several alternative splicing products, one of which, the KTS+ variant, has been demonstrated to be involved in the transcriptional activation of a variety of oncogenes as well as the inhibition of tumor suppressor genes. Further, this paper will examine the relationship of WT1 with CD97, a gene that codes for an epidermal growth factor receptor family member, an adhesion G-protein–coupled receptor, thought to promote tumor invasiveness and migration. The authors suggest that further research into WT1 and CD97 will allow clinicians to begin to deal more effectively with the infiltrative behavior displayed by GBM and design new therapies that target this deadly disease.

show abstract

Section: Gbm and Wilms Tumormentioning

confidence: 93%

Section: Gbm and Wilms Tumormentioning

confidence: 93%

Wilms tumor 1 gene, CD97, and the emerging biogenetic profile of glioblastoma

Somasundaram

Ardanowski

Opalak

et al. 2014

FOC

View full text Add to dashboard Cite

show abstract

“…According to the WHO classification of central nervous system tumors, glioma is divided into four different grades depending on the malignant potential. Immunohistochemical analyses demonstrated that WT1 is expressed in many gliomas (5,(26)(27)(28)(29) (Figure 1) and expression is variable depending on the tumor grade. In less-aggressive grade II glioma and diffuse astrocytoma, WT1 expression was lower than that in grade IV glioblastoma.…”

Section: Gliomamentioning

confidence: 99%

“…In less-aggressive grade II glioma and diffuse astrocytoma, WT1 expression was lower than that in grade IV glioblastoma. Furthermore, Rauscher et al (29) reported that WT1 expression is a prognostic marker of WHO grade II and III tumors, and WT1 expression is reduced in recurrent tumors.…”

Section: Gliomamentioning

confidence: 99%

See 1 more Smart Citation

Functional Roles of Wilms’ Tumor 1 (WT1) in Malignant Brain Tumors

et al. 2016

View full text Add to dashboard Cite

Copyright: The Authors.Licence: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/ Users are allowed to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. AbstractThe pleiotropic transcription factor, Wilms' tumor 1 (WT1), is expressed in the majority of glioblastomas, the most common malignant brain tumors of adulthood. Despite intensive treatment, including surgery and chemoradiotherapy, the prognosis for patients with glioblastoma remains very poor. Encouragingly, immunotherapy targeting WT1 has proven to be effective in recurrent glioblastoma, suggesting that Kijima et al. 262 this approach may be an important new treatment modality for the disease. However, WT1 appears to function as a context-dependent tumor suppressor or oncogene, and the functional roles of WT1 in the pathogenesis of glioblastoma, and other types of brain tumors, have not been extensively studied. With this in mind, we briefly review WT1 expression data for a range of different brain tumor classes and address the role of WT1 in the regulation of proliferation and apoptosis in glioblastoma. We generated WT1 knockdown glioblastoma cells by using shRNA-expressing lentivirus. Proliferation was reduced and apoptosis increased in WT1 knockdown glioblastoma cells compared with control cells in vitro. Consistent with these data, when WT1 knockdown glioblastoma cells or control glioblastoma cells were intracranially injected into the immunodeficient mice, tumor growth was significantly reduced in WT1 knockdown cells compared with that in control cells. Thus, WT1 is an oncogene that regulates cell proliferation and apoptosis in glioblastoma.

show abstract